Verve Therapeutics Inc (NQ: VERV )
4.470
-0.070
(-1.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
All News about Verve Therapeutics Inc
![](https://cdn.benzinga.com/files/images/story/2022/12/05/image20.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/05/image-vf_corp.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/05/image44.jpg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/10/Stock-vervetherapeutics-01-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_22059.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/708218/scientist-looking-through-microscope.jpg)
![](https://www.investors.com/wp-content/uploads/2022/10/Stock-vervetherapeutics-01-adobe.jpg)
![](https://ml.globenewswire.com/media/2a4edc4b-98df-4e32-ade8-159b39872434/small/verve-logo-rgb-color-wtrademark-png.png)
Verve Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2022
From Verve Therapeutics
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/11/08/image16.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image44.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_20875.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image14.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_20868.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image17.jpg?width=1200&height=800&fit=crop)
![](https://schaeffers-cdn.s3.amazonaws.com/images/default-source/schaeffers-cdn-images/2022/october/mmc/mmc-nov7.jpg?sfvrsn=da0ead06_2)
![](https://investorplace.com/wp-content/uploads/2021/02/auction.png)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/verv_logo_light__275e9401a6b8fe6d5a24270564eff9aa.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2020/06/fda-food-drug.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image-treehouse_foods.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image31.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/11/Stock-vervetherapeutics-02-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_20835.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-stock-market.jpg)
![](https://ml.globenewswire.com/media/2a4edc4b-98df-4e32-ade8-159b39872434/small/verve-logo-rgb-color-wtrademark-png.png)
![](https://ml.globenewswire.com/media/2a4edc4b-98df-4e32-ade8-159b39872434/small/verve-logo-rgb-color-wtrademark-png.png)
![](https://www.investors.com/wp-content/uploads/2022/10/A1MAIN_GeneEdit_102122.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/valuestock_image_3268.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/10/06/aapharma_12.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2019/07/tsla1600d.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_5067.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
October 06, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.